Patients with severe idiopathic pulmonary fibrosis (IPF) often develop additional pulmonary hypertension. A clinical trial investigated whether treatment with Sildenafil (approved for PH) when administered in addition to the pulmonary fibrosis medication pirfenidone is effective.
A research team from Hannover with participation of the DZL have published a study on molecular markers for various forms of pulmonary hypertension in the American Journal of Pathology.
The collaborative research center 1213 for cardiopulmonary research in Giessen, spear-headed by DZL scientist Prof. Dr. Norbert Weissmann, will be funded by the German Re-search Foundation (DFG) for another four years. The first funding period...
Soni Savai Pullamsetti Receives 2 Million Euro Research Grant from the European Research Council.
Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease of the pulmonary vasculature. Affected patients have a poor prognosis, and treatment options are limited.
The DZL was represented with an information desk at the 60th Congress of the German Respiratory Society (DGP), which took place in Munich from March 13–16, 2019.
Pulmonary Hypertension (PH) is a severe condition of the lungs and the heart, which cannot be cured.
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension – DZL scientists of…
...for his game-changing research in the area of Pulmonary Hypertension...
Prof. Dr. Werner Seeger gave the 2014 Dickinson W. Richards Memorial Lecture at the American Heart Association Meeting in Chicago.
DZL UGMLC researchers discover a new therapeutic approach for treating pulmonary hypertension.
